Kymera Investor Day Presentation Deck slide image

Kymera Investor Day Presentation Deck

Skin KT-474 Concentration (ng/g) Mean (± SD) 400 Once Daily Dosing (14 Days) Resulted in High Skin Exposures Exceeding Plasma 300- 200 100 ● ● KT-474 Levels in Skin 7 14 Day 25 mg QD 50 mg QD Ctrough concentrations shown for Days 1, 7 and 14. KYMERA ©2021 KYMERA THERAPEUTICS, INC. 100 mg QD A 200 mg QD T 28 Increasing exposures through Day 14 Ctrough levels in skin ~10-14 fold higher than plasma on Day 14 Substantially Larger Skin vs Plasma Exposures at Ctrough [ng/mL for Plasma, ng/g for Skin] Mean (± SD) Concentration 150- 100 50 ng/mL (plasma) ng/g (skin) Plasma Day 7 Plasma Day 14 Skin Day 7 Skin Day 14 Plasma Day 7 Plasma Day 14 Skin Day 7 Skin Day 14 KYMERA R&D DAY - December 16th, 2021 25 mg QD (n=9) 3.21 4.72 21.5 44.5 50 mg QD (n=9) 7.15 8.49 40.2 94.2 100 mg QD (n=9) 11.9 11.6 53.5 93.7 H 200 mg QD (n=9) 18.2 17.4 80.9 238 PAGE 37
View entire presentation